Screening for thrombophilia and antithrombotic prophylaxis in pregnancy: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET).

[1]  A. Fouda.  Thromboprophylaxis During Pregnancy, Labour and After Vaginal Delivery , 2011 .

[2]  W. Ageno,et al.  Objectives and methodology: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). , 2009, Thrombosis research.

[3]  F. Rosendaal,et al.  Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study , 2008, Journal of thrombosis and haemostasis : JTH.

[4]  P. Mannucci,et al.  The risk of first venous thromboembolism during pregnancy and puerperium in double heterozygotes for factor V Leiden and prothrombin G20210A , 2008, Journal of thrombosis and haemostasis : JTH.

[5]  M. Margaglione,et al.  The G20210A prothrombin variant and the risk of venous thromboembolism or fetal loss in pregnant women: a family study , 2007, Journal of thrombosis and haemostasis : JTH.

[6]  H. Kluin-Nelemans,et al.  The Pathogenesis of Venous Thromboembolism: Evidence for Multiple Interrelated Causes , 2006, Annals of Internal Medicine.

[7]  S. Kahn,et al.  Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. , 2006, The Journal of rheumatology.

[8]  G. Leone,et al.  The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis , 2006 .

[9]  E. Oger,et al.  Incidence of venous thromboembolism in first-degree relatives of patients with venous thromboembolism who have factor V Leiden , 2006, Thrombosis and Haemostasis.

[10]  J. Gris,et al.  More on: factor V Leiden and prothrombin G20210A polymorphisms as risk factors for miscarriage during a first intended pregnancy: the matched case‐control ‘NOHA First’ study , 2006, Journal of thrombosis and haemostasis : JTH.

[11]  E. Hachulla,et al.  Use of low-molecular-weight heparin from the first trimester of pregnancy: a retrospective study of 111 consecutive pregnancies. , 2006, European journal of obstetrics, gynecology, and reproductive biology.

[12]  J. Daurès,et al.  Factor V Leiden mutation and pregnancy-related venous thromboembolism: What is the exact risk? , 2006, Thrombosis and Haemostasis.

[13]  M Greaves,et al.  Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. , 2006, Health technology assessment.

[14]  B. Dahlbäck,et al.  Activated protein C resistance – in the absence of factor V Leiden – and pregnancy , 2006, Journal of thrombosis and haemostasis : JTH.

[15]  Y. Shoenfeld,et al.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) , 2006, Journal of thrombosis and haemostasis : JTH.

[16]  P. Langhorne,et al.  Thrombophilia in pregnancy: a systematic review , 2006, British journal of haematology.

[17]  B. Sibai,et al.  The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus. , 2006, Obstetrics and gynecology.

[18]  K. Bailey,et al.  Trends in the Incidence of Venous Thromboembolism during Pregnancy or Postpartum: A 30-Year Population-Based Study , 2005, Annals of Internal Medicine.

[19]  I. Greer,et al.  Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. , 2005, Blood.

[20]  A. Kaider,et al.  Risk of pregnancy‐associated recurrent venous thromboembolism in women with a history of venous thrombosis , 2005, Journal of thrombosis and haemostasis : JTH.

[21]  J. Craig,et al.  Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. , 2005, The Cochrane database of systematic reviews.

[22]  M. Rodger,et al.  A systematic review of the association between factor V Leiden or prothrombin gene variant and intrauterine growth restriction. , 2005, American journal of obstetrics and gynecology.

[23]  B. Brenner,et al.  Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy loss: the LIVE‐ENOX study , 2005, Journal of thrombosis and haemostasis : JTH.

[24]  S. Gates,et al.  Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low-molecular-weight heparin. , 2004, American journal of obstetrics and gynecology.

[25]  M. Prins,et al.  Prothrombin 20210A mutation: a mild risk factor for venous thromboembolism but not for arterial thrombotic disease and pregnancy-related complications in a family study. , 2004, Archives of internal medicine.

[26]  J. Ioannidis,et al.  Association of C677T polymorphism in the methylenetetrahydrofolate reductase gene with hypertension in pregnancy and pre-eclampsia: a meta-analysis , 2004, Journal of hypertension.

[27]  J. Hirsh,et al.  Use of antithrombotic agents during pregnancy: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[28]  J. Gris,et al.  Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. , 2004, Blood.

[29]  K. Barnhart,et al.  Evaluation of the association between hereditary thrombophilias and recurrent pregnancy loss: a meta-analysis. , 2004, Archives of internal medicine.

[30]  J. Attia,et al.  The association between adverse pregnancy outcomes and maternal factor V Leiden genotype: a meta-analysis , 2004, Thrombosis and Haemostasis.

[31]  U. John,et al.  Factor V Leiden and the risk of stillbirth in a German population , 2003, Thrombosis and Haemostasis.

[32]  R. North,et al.  Prophylactic and therapeutic enoxaparin during pregnancy: Indications, outcomes and monitoring , 2003, The Australian & New Zealand journal of obstetrics & gynaecology.

[33]  S. Kahn,et al.  Thrombophilic disorders and fetal loss: a meta-analysis , 2003, The Lancet.

[34]  S. Twaddle,et al.  Cost-effectiveness of screening for the factor V Leiden mutation in pregnant women , 2002, The Lancet.

[35]  E. Taioli,et al.  Inherited Thrombophilia and First Venous Thromboembolism during Pregnancy and Puerperium , 2002, Thrombosis and Haemostasis.

[36]  D. Roberts,et al.  How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. , 2002, European journal of obstetrics, gynecology, and reproductive biology.

[37]  M. Margaglione,et al.  Impact of prothrombotic mutations and family history on the occurrence of intra-uterine fetal deaths. , 2002, Haematologica.

[38]  A. Borel‐Derlon,et al.  Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies , 2001, BJOG : an international journal of obstetrics and gynaecology.

[39]  E. Grandone,et al.  Risk of Pregnancy-related Venous Thrombosis in Carriers of Severe Inherited Thrombophilia , 2001, Thrombosis and Haemostasis.

[40]  P. Prandoni,et al.  Pregnancy-related Recurrent Events in Thrombophilic Women with Previous Venous Thromboembolism , 2001, Thrombosis and Haemostasis.

[41]  H. Büller,et al.  The risk of pregnancy‐related venous thromboembolism in women who are homozygous for factor V Leiden , 2001, British journal of haematology.

[42]  J. Hirsh,et al.  Safety of Withholding Heparin in Pregnant Women With a History of Venous Thromboembolism , 2001 .

[43]  P. Prandoni,et al.  Factor V Leiden mutation and the risk of venous thromboembolism in pregnant women. , 2001, Haematologica.

[44]  J. Hirsh,et al.  Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. , 2000, The New England journal of medicine.

[45]  I. Greer,et al.  Antenatal use of enoxaparin for prevention and treatment of thromboembolism in pregnancy , 2000, BJOG : an international journal of obstetrics and gynaecology.

[46]  S. Moll,et al.  Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. , 2000, The New England journal of medicine.

[47]  R. Zotz,et al.  Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. , 2000, The New England journal of medicine.

[48]  D. Fitzgerald,et al.  Prospective evaluation of the risk conferred by factor V Leiden and thermolabile methylenetetrahydrofolate reductase polymorphisms in pregnancy. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[49]  V. Pettilä,et al.  Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. , 1999, Thrombosis research.

[50]  P. Prandoni,et al.  The Risk of Fetal Loss in Family Members of Probands with Factor V Leiden Mutation , 1999, Thrombosis and Haemostasis.

[51]  K. Maršál,et al.  Thrombotic risk during pregnancy: a population study. , 1999, Obstetrics and gynecology.

[52]  M. Prins,et al.  Increased Risk for Fetal Loss in Carriers of the Factor V Leiden Mutation , 1999, Annals of Internal Medicine.

[53]  B. Brenner,et al.  Safety of Low-Molecular-Weight Heparin in Pregnancy: A Systematic Review , 1999, Thrombosis and Haemostasis.

[54]  I. Greer.  Thrombosis in pregnancy: maternal and fetal issues , 1999, The Lancet.

[55]  K. Maršál,et al.  Activated Protein C Resistance (FV:Q506) and Pregnancy , 1999, Thrombosis and Haemostasis.

[56]  M. Prins,et al.  Incidence of Venous Thromboembolism in Families with Inherited Thrombophilia , 1999, Thrombosis and Haemostasis.

[57]  R. Tait,et al.  Superficial Vein Thrombosis: Incidence in Association with Pregnancy and Prevalence of Thrombophilic Defects , 1998, Thrombosis and Haemostasis.

[58]  M. Blombäck,et al.  Thromboprophylaxis with low molecular mass heparin, 'Fragmin' (dalteparin), during pregnancy--a longitudinal safety study. , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[59]  M. Prins,et al.  The Incidence of Venous Thromboembolism in Family Members of Patients with Factor V Leiden Mutation and Venous Thrombosis , 1998, Annals of Internal Medicine.

[60]  R. Tait,et al.  Risk Factors for Pregnancy Associated Venous Thromboembolism , 1997, Thrombosis and Haemostasis.

[61]  C. Nelson-Piercy,et al.  Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. , 1997, American journal of obstetrics and gynecology.

[62]  K. Ward,et al.  The incidence of the factor V Leiden mutation in an obstetricpopulation and its relationship to deep vein thrombosis , 1997, American journal of obstetrics and gynecology.

[63]  G. Hughes,et al.  Thromboprophylaxis with Low Molecular Weight Heparin (Fragmin) in High Risk Pregnancies , 1997, Thrombosis and Haemostasis.

[64]  M. Prins,et al.  Frequency of Pregnancy-Related Venous Thromboembolism in Anticoagulant Factor-Deficient Women: Implications for Prophylaxis , 1996, Annals of Internal Medicine.

[65]  I. Pabinger,et al.  Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[66]  T. Barbui,et al.  Thrombosis during Pregnancy and Surgery in Patients with Congenital Deficiency of Antithrombin III, Protein C, Protein S , 1994, Thrombosis and Haemostasis.

[67]  T. Dahlman,et al.  Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. , 1993, American journal of obstetrics and gynecology.

[68]  Jeffrey S. Ginsberg,et al.  Use of antithrombotic agents during pregnancy. , 1992, Chest.

[69]  D. Bergqvist,et al.  Recurrent thromboembolism in pregnancy and puerperium. Is there a need for thromboprophylaxis? , 1989, American journal of obstetrics and gynecology.

[70]  M. Swiet,et al.  The risks of antenatal subcutaneous heparin prophylaxis: a controlled trial , 1983, British journal of obstetrics and gynaecology.